Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Signs Collaboration Agreement with Sysmex Inostics

Published: Sunday, June 01, 2014
Last Updated: Wednesday, June 04, 2014
Bookmark and Share
Collaboration for the development and commercialization of a blood-based RAS biomarker test.

Merck announced today that the company has signed an agreement to collaborate with Sysmex Inostics GmbH, Hamburg, Germany, for the development and commercialization of a blood-based RAS biomarker test for patients with metastatic colorectal cancer (mCRC). This global agreement was formally signed at a ceremony coinciding with the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, U.S.

Blood-based biomarker testing is a faster and easier approach for determining the mutation status of tumors as it requires a small blood sample rather than a tissue biopsy procedure.1 The test has the potential to provide mutation status results within days, which in turn can help guide treatment decisions.1 In addition, it may become the method of choice where a tissue biopsy is difficult to obtain, for example in patients whose physical condition does not allow for a surgical procedure.

“We are delighted to announce our strategic partnership with Sysmex Inostics,” said Belén Garijo, President and CEO of Merck Serono. “As a company, we have embraced the principles of personalized medicine and predictive biomarkers. This collaboration reflects our commitment to leveraging our expertise in personalized medicine and predictive biomarkers in order to enhance Erbitux’s value proposition for patients, physicians and payers.”

“We are looking forward to this important collaboration with Merck Serono and to bringing our innovative technology to mCRC patients,” said Fernando Andreu, CEO of Sysmex Inostics. “Together with our non-invasive, blood-based diagnostics and Merck’s expertise in personalized medicine, we will open up new possibilities to advance biomarker testing in mCRC. This collaboration is another major step in enhancing the clinical value of Sysmex Inostics’s OncoBEAM tests and exemplifies Sysmex’s overall strategy to bring sensitive blood-based testing to the Oncology field.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test
Companies to develop and commercialize of a RAS kit for patients with metastatic colorectal cancer (mCRC).
Wednesday, June 04, 2014
Apitope and Merck Serono Announce Licensing Agreement on Peptide Therapeutics for Multiple Sclerosis
Under this agreement, Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467.
Wednesday, January 14, 2009
New President of Merck Research Laboratories Named

Tuesday, December 03, 2002
Scientific News
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Oxitec ‘Self-Limiting Gene’ Offers Hope for Controlling Invasive Moth
A new pesticide-free and environmentally-friendly way to control insect pests has moved ahead with the publication of results showing that Oxitec diamondback moths (DBM) with a ‘self-limiting gene’ can dramatically reduce populations of DBM.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
Scientists Identify Schizophrenia’s “Rosetta Stone” Gene
Scientists have identified a critical function of what they believe to be schizophrenia’s “Rosetta Stone” gene that could hold the key to decoding the function of all genes involved in the disease.
Could a simple saliva test detect Alzheimer's?
Researchers have presented findings suggesting that a simple, non-invasive diagnostic for Alzheimer's could be within reach.
New Research Advances Genetic Studies in Wildlife Conservation
‘Next-gen’ DNA sequencing of non-invasively collected hair expands field of conservation genetics.
AncestryDNA and Calico to Research the Genetics of Human Lifespan
Collaboration will analyze family history and genetics to facilitate development of cutting-edge therapeutics.
Gene Variation Identified for Teen Binge-Eating
Researchers have identified a gene variant which can lead to teenage binge eating, they hope that their work will inform the development of future preventative measures.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!